Invitrogen Expects Greater Cost Savings Post-Merger; ABI Reaffirms Q1 Forecast | GenomeWeb
NEW YORK (GenomeWeb News) – Invitrogen said today that it expects synergies from its pending $6.7 billion merger with Applied Biosystems to be at least $80 million in the first year after close, instead of the $60 million initially forecasted by the firm. It said these synergies are mostly attributable to cost savings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.